Involvement of γδ T Cells in Respiratory Virus Infections
Some aspects of the immunobiology of virus-induced respiratory disease are relatively well understood. It is known, for instance, that the adoptive transfer of cloned CD8+ T cells to immunologically naive mice infected intranasally (i.n.) with an influenza A virus greatly enhances virus clearance (Lukacher et al 1984, Taylor & Askonas 1986). The same has been observed for cloned CD4+ T cells, though the kinetics of virus elimination are more protracted (Lukacher et al 1986). In both cases, the effect is mediated by T cells that are conventionally MHOrestricted and are very specific for the infecting pathogen. There is thus no doubt that effector functions mediated by αβ T cell receptor (TCR)-bearing lymphocytes are of central importance in recovery from infection of the respiratory tract with influenza A viruses. Recent studies of the influenza pneumonia model have established that there is substantial involvement of lymphocytes with mRNA for the γδ TCR late in the course of the inflammatory process, after infectious virus has been eliminated (Allan et al 1990, Carding et al 1990 a). The obvious question is whether these γδ T cells contribute to the specific host response, or are simply recruited passively by the αβ TCR+ effectors (Doherty et al 1990).
KeywordsPneumonia Influenza Mycobacterium
Unable to display preview. Download preview PDF.
- Kilbourne ED (1969) Future influenza vaccines and the use of genetic recombinants. Bull Wld Hlth Org 41:643–645.Google Scholar
- Kubo RT, Born W, Kappler JW, Marrack P, Pigeon M (1989) Characterization of a monoclonal antibody which detects all murine αβ T cell receptors. J Immunol 142:2126–2142.Google Scholar
- Lukacher AE, Morrison LA, Braciale VL, Braciale TJ (1986) T lymphocyte recovery from experimental viral infection. In: Steinman RM, North RJ (eds) The Rockefeller University Press, New York p 223.Google Scholar
- Taylor PM, Askonas BA (1986) Influenza nucleoprotein-specific cytotoxic T cell clones are protective in vivo. Immunol 58:417–420.Google Scholar